News – Page 75 – Endpoints News

Bristol Myers reveals more job cuts in New Jersey

6 months ago

Trump team asked Warp Speed leader to head NIH, may seek more traditional pick for role

6 months ago

Minnesota 340B revenue driven by hospitals and high-priced drugs, first state report says

6 months ago

Merck halts Phase 3 trial with PAH drug Winrevair following positive interim data

6 months ago

Incyte touts Monjuvi data from Phase 3 follicular lymphoma trial as it heads to FDA

6 months ago

Cassava shares plunge as controversial Alzheimer’s drug fails Phase 3 trial

6 months ago

Biohaven's myostatin inhibitor misses primary endpoint in spinal muscular atrophy trial

6 months ago

Replimune aims to raise $125M; Otsuka makes another deal with Ionis

6 months ago

Gilead buys experimental HIV vaccines from a small Barcelona biotech

6 months ago

ADC biotech Adcendo nabs $135M Series B as it enters the clinic

6 months ago

AstraZeneca’s Truqap edges closer to prostate cancer label expansion with Phase 3 win

6 months ago

Trump announces picks for FDA, CDC; Novartis seeks bolt-on deals, raises guidance; RFK Jr., Elon Musk may find ...

6 months ago

For CDC, Trump picks Dave Weldon, a former congressman who pushed for vaccine injury claims

6 months ago

Trump taps Johns Hopkins researcher Marty Makary to lead the FDA; also names CDC, surgeon general picks

6 months ago

FDA approves BridgeBio's heart disease drug, setting up competition with Pfizer, Alnylam

6 months ago

Sanofi introduces new 340B payment model — report

6 months ago

Drug or biologic? An Eli Lilly lawsuit could impact weight loss drug compounders

6 months ago

Senate Judiciary Committee advances patent bill with new protections for pharma challenges

6 months ago

From vaccines to psychedelics, five drugmakers on what could change under a Trump administration

6 months ago

Halozyme withdraws Evotec acquisition proposal after biotech is 'unwilling to engage'

6 months ago

Lexicon ends commercial work to focus on R&D

6 months ago

Surrounded by AI bio giants, tiny startup Nabla Bio makes de novo antibodies look more like drugs

6 months ago

Lilly's board undergoes more changes; Merck strategy chief joins Roger Perlmutter at Eikon

6 months ago

Microsoft-backed Enveda raises $130M for drugs in I&I, obesity and other areas

6 months ago

First page Previous page 72 73 747576 77 78 Next page Last page